← All Avadel Pharmaceuticals PLC filings

Avadel Pharmaceuticals PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AVDL
Avadel Pharmaceuticals PLC
10-K: Avadel Pharmaceuticals Reports FY2024 Results, Highlights LUMRYZ Commercial Progress
Avadel Pharmaceuticals' 10-K filing summarizes the company's financial performance for 2024, focusing on the commercialization of LUMRYZ and its future prospects.
AVDL
Avadel Pharmaceuticals PLC
10-K/A: Avadel Pharmaceuticals Files Amendment to 2023 Annual Report on Form 10-K
Avadel Pharmaceuticals has filed an amendment to its 2023 annual report to include previously omitted information regarding directors, executive officers, and corporate governance.
AVDL
Avadel Pharmaceuticals PLC
10-K: Avadel Pharmaceuticals Outlines Share Structure and Corporate Governance in SEC Filing
Avadel Pharmaceuticals details its share capital, including ordinary and preferred shares, and outlines key corporate governance provisions in a recent SEC filing.